R&D Trends

Sosei subsidiary Heptares and Allergan partner

Thursday, April 7, 2016

Sosei Group‘s wholly-owned subsidiary Heptares Therapeutics has entered into a definitive agreement with Allergan Pharmaceuticals International, a wholly owned subsidiary of Allergan, a global pharmaceutical company, under which Allergan will license exclusive global rights to a broad portfolio of novel subtype-selective muscarinic receptor agonists in development for the treatment of major neurological disorders, including Alzheimer’s disease.

[Read More]

FEI partners to form Cryo-EM research consortium

Tuesday, April 5, 2016

FEI has partnered to form the “Cambridge Pharmaceutical Cryo-EM Consortium.” Partners include five pharmaceutical companies—Astex Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Heptares Therapeutics and UCB; the Medical Research Council Laboratory of Molecular Biology (MRC-LMB); and the University of Cambridge’s Nanoscience Center. As part of the three-year agreement, FEI will provide sample preparation and data collection services on a Titan Krios cryo-transmission electron microscope (cryo-EM) to the consortium companies for early-stage drug discovery research.

[Read More]

Report: Slowest quarter for venture-backed IPOs since 2011

Tuesday, April 5, 2016

Six venture-backed initial public offerings (IPOs) raised $574.5 million in the first quarter of 2016, according to the Exit Poll Report by Thomson Reuters and the National Venture Capital Association (NVCA). This marks the slowest quarter for venture-backed IPOs since the third quarter of 2011. By merger and acquisition (M&A), 79 venture-backed M&A deals were reported in the first quarter, 20 of which reported an aggregate deal value of $4.8 billion.   

[Read More]

Dotmatics, BioByte partner to speed drug candidate selection

Tuesday, April 5, 2016

Dotmatics, a provider of scientific informatics solutions and services to the life sciences industry, announced a partnership with BioByte, producer of the industry gold standard partition coefficient calculator (ClogP). This deal will enable users of the Dotmatics Platform including Vortex and Browser to calculate ClogP seamlessly within the applications. This will streamline the research process and speed up the selection of potential drug candidates.  

[Read More]

Dana-Farber, Ontario Institute join collaborative cancer cloud

Friday, April 1, 2016

The Knight Cancer Institute at Oregon Health & Science University and Intel are expanding participation in the Collaborative Cancer Cloud, a distributed precision medicine analytics platform, to include Dana-Farber Cancer Institute and Ontario Institute for Cancer Research. The institutions will join the OHSU Knight Cancer Institute in leveraging Intel’s technology to securely share and analyze their collectively large amounts of data, while preserving the privacy and security of patient data at each site.

[Read More]

Orig3n, Sharp Edge Labs ink drug discovery alliance

Monday, March 28, 2016

ORIG3N, a regenerative medicine provider, and Sharp Edge Labs, a drug discovery and development company focused on genetic disorders, have entered into a drug discovery alliance. As part of the alliance, ORIG3N will make patient-derived cells available to Sharp Edge Labs for use in their drug discovery platform for genetic disorders.

[Read More]

Paul G. Allen Frontiers Group to launch for ‘out-of-the-box’ research

Thursday, March 24, 2016

Philanthropist and entrepreneur Paul G. Allen has announced an initial commitment of $100 million to create The Paul G. Allen Frontiers Group, whose purpose will be to explore the landscape of bioscience and fund ideas at the frontier of knowledge to advance science and make the world better. As part of the launch, the Frontiers Group announces its first cohort of funded projects with four new Allen Distinguished Investigators (ADI) and two Allen Discovery Centers in partnership with Stanford University and Tufts University.

[Read More]